Verastem’s duvelisib was seen to outperform Arzerra (ofatumumab) in a Phase 3 trial of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the company announced.
The oral therapy nearly halved the risk of disease progression or death, and held patients progression-free for a median of 13.3 months. This was 3.4 months longer than in patients treated with Arzerra.
Source: phx.corporate-ir.net/phoeni...
Beyond the Diagnosis: Surviving and Thriving with CLL / SLL VenR in Relapsed CLL: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations from MURANO 3 studyIbrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with CLL
EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor
A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lym
